X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3112) 3112
Book Review (590) 590
Publication (234) 234
Book Chapter (59) 59
Conference Proceeding (12) 12
Dissertation (7) 7
Book / eBook (2) 2
Data Set (2) 2
Newspaper Article (2) 2
Magazine Article (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2279) 2279
humans (1910) 1910
female (1116) 1116
male (1105) 1105
dosing (1047) 1047
pharmacology & pharmacy (994) 994
pharmacokinetics (792) 792
middle aged (763) 763
adult (688) 688
aged (622) 622
drug administration schedule (506) 506
dose-response relationship, drug (505) 505
pharmacology (446) 446
analysis (415) 415
treatment outcome (396) 396
drug dosages (394) 394
therapy (382) 382
patients (366) 366
animals (331) 331
dosing regimen (328) 328
drug therapy (308) 308
pharmacodynamics (281) 281
efficacy (272) 272
oncology (272) 272
safety (269) 269
aged, 80 and over (266) 266
adolescent (258) 258
retrospective studies (244) 244
dosage and administration (232) 232
drugs (229) 229
anti-bacterial agents - administration & dosage (221) 221
care and treatment (221) 221
medicine & public health (220) 220
children (214) 214
research (214) 214
clinical trials (210) 210
infectious diseases (209) 209
health aspects (204) 204
child (195) 195
models, biological (195) 195
cancer (190) 190
young adult (188) 188
prospective studies (185) 185
population pharmacokinetics (180) 180
adherence (179) 179
anti-bacterial agents - pharmacokinetics (179) 179
toxicity (174) 174
pediatrics (169) 169
pharmacology/toxicology (168) 168
time factors (168) 168
medical research (167) 167
administration, oral (161) 161
antibiotics (161) 161
medicine (161) 161
microbiology (153) 153
dosing regimens (152) 152
body weight (148) 148
patient compliance (148) 148
internal medicine (143) 143
studies (141) 141
hematology (140) 140
algorithms (135) 135
chemotherapy (135) 135
medicine, general & internal (135) 135
computer simulation (134) 134
warfarin (134) 134
research article (132) 132
dosing frequency (131) 131
double-blind method (129) 129
pharmacogenetics (127) 127
vancomycin (127) 127
child, preschool (125) 125
infections (125) 125
pharmacy (125) 125
double-blind (123) 123
management (122) 122
toxicology (120) 120
immunology (119) 119
risk factors (117) 117
abridged index medicus (116) 116
dosage (115) 115
ophthalmology (114) 114
usage (112) 112
infant (110) 110
rats (110) 110
trial (109) 109
aminoglycosides (108) 108
medicine, experimental (108) 108
medicine, research & experimental (108) 108
article (107) 107
prevention (107) 107
genotype (105) 105
metabolism (105) 105
exposure (104) 104
mortality (103) 103
multidisciplinary sciences (102) 102
anticoagulants - administration & dosage (101) 101
infants (101) 101
psychiatry (101) 101
adults (100) 100
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3129) 3129
German (14) 14
French (11) 11
Japanese (8) 8
Spanish (8) 8
Russian (6) 6
Korean (4) 4
Czech (2) 2
Polish (2) 2
Portuguese (2) 2
Chinese (1) 1
Hungarian (1) 1
Italian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Therapeutics, ISSN 0149-2918, 2005, Volume 27, Issue 4, pp. 393 - 406
A patient-driven, adjustable maintenance dosing (AMD) approach to asthma therapy, in which the dose is adjusted by patients according to the severity of their... 
adjustable maintenance dosing | salmeterol/fluticasone propionate | formoterol/budesonide | asthmacontrol | exacerbations | Exacerbations | Salmeterol/fluticasone propionate | Formoterol/budesonide | Asthma control | Adjustable maintenance dosing | LONG-ACTING BETA-AGONISTS | MANAGEMENT | INHALED CORTICOSTEROIDS | AIRWAY INFLAMMATION | BUDESONIDE | asthma control | COMBINATION | HYPERRESPONSIVENESS | THERAPY | PHARMACOLOGY & PHARMACY | Bronchodilator Agents - therapeutic use | Ethanolamines - adverse effects | Formoterol Fumarate | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Male | Fluticasone | Ethanolamines - administration & dosage | Self Administration - methods | Albuterol - administration & dosage | Adult | Female | Bronchodilator Agents - adverse effects | Asthma - classification | Salmeterol Xinafoate | Double-Blind Method | Albuterol - analogs & derivatives | Treatment Outcome | Asthma - drug therapy | Androstadienes - administration & dosage | Budesonide - adverse effects | Budesonide - therapeutic use | Albuterol - therapeutic use | Ethanolamines - therapeutic use | Androstadienes - therapeutic use | Budesonide - administration & dosage | Androstadienes - adverse effects | Albuterol - adverse effects | Drug Combinations | Analysis | Propionates | Clinical trials | Adults | Dosage and administration | Steroids | Asthma | Index Medicus
Journal Article
CANCER, ISSN 0008-543X, 06/2010, Volume 116, Issue 12, pp. 2868 - 2877
Journal Article
Intensive Care Medicine, ISSN 0342-4642, 7/2014, Volume 40, Issue 7, pp. 998 - 1005
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2017, Volume 12, Issue 6, pp. e0179927 - e0179927
Journal Article
AIDS, ISSN 0269-9370, 11/2010, Volume 24, Issue 18, pp. 2835 - 2840
Background: Although, single-tablet regimen (STR) efavirenz, emtricibine, and tenofovir disoproxil fumarate (EFV/FTC/TDF) may be appealing in HIV-infected... 
dosing frequency | POPULATION | INFECTIOUS DISEASES | mental illness | LOAD | adherence | pill-burden | homeless | once daily | AIDS | IMMUNOLOGY | NAIVE | one pill | VIROLOGY | INHIBITOR THERAPY | ACTIVE ANTIRETROVIRAL THERAPY | RESISTANCE | drug use | COHORT | OUTCOMES | PROTEASE
Journal Article
European Journal of Cancer, ISSN 0959-8049, 05/2019, Volume 113, pp. 28 - 31
Nivolumab and pembrolizumab were initially developed using weight-based regimen doses. Recently, fixed-dose regimens were commercialised with reference weights... 
Fixed-dose regimens | Anti–PD-1/PD-L1 | Budget impact | Immunotherapy | Anti-PD-1/PD-L1 | PEMBROLIZUMAB | ONCOLOGY | NIVOLUMAB | DOCETAXEL | Economic aspects | Biochemistry | Lung cancer | Apoptosis | Health care | Dosing | Economic analysis | PD-1 protein | Melanoma | Patients | Data bases | Weight | Impact analysis | Proteins | Confidence intervals | Infusion | Hydrologic data | Pembrolizumab | Databases | Cell death | Economic impact | Budgets | Commercialization | Cancer
Journal Article
Annals of Oncology, ISSN 0923-7534, 08/2017, Volume 28, Issue 8, pp. 2002 - 2008
Background: Nivolumab 3 mg/kg every 2 weeks (Q2W) has shown benefit versus the standard of care in melanoma, non-small cell lung cancer (NSCLC), and renal cell... 
Clinical pharmacology | Flat dosing | Solid tumors | Cancer immunotherapy | Nivolumab | Exposure-response relationship | exposure-response relationship | MELANOMA | nivolumab | ONCOLOGY | cancer immunotherapy | clinical pharmacology | DOCETAXEL | flat dosing | solid tumors | Index Medicus | Original articles | Editor's Choice | exposure–response relationship
Journal Article
International Journal of Clinical Pharmacy, ISSN 2210-7703, 10/2018, Volume 40, Issue 5, pp. 1059 - 1071
Journal Article
Retina, ISSN 0275-004X, 12/2016, Volume 36, Issue 12, pp. 2282 - 2289
Journal Article